A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 46086
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : OS
Long Form : overall survival
No. Year Title Co-occurring Abbreviation
2020 18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. DLBCL, MTV, PFS
2020 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. SUV, TLF
2020 1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. HCC, OPLS-DA
2020 25-Hydroxy vitamin D deficiency predicts inferior prognosis in mantle cell lymphoma. AUC, CI, HR, MCL, NHL, PFS, ROC
2020 3D visualization ablation planning system assisted microwave ablation for hepatocellular carcinoma (Diameter >3): a precise clinical application. HCC, LTP, RFS, US-PMWA
2020 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia-a summary. DC-CIK, NK, RFS
2020 A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? CI, CRS, HR, NACT, PFS
2020 A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. CI, CS, DCF, ICT, PFS
2020 A comparison of spinal laser interstitial thermotherapy with open surgery for metastatic thoracic epidural spinal cord compression. ESCC, LOS, PFS, SLITT, SSRS
10  2020 A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. CI, HR, PFS, STSs
11  2020 A large-scale transcriptome analysis identified ELANE and PRTN3 as novel methylation prognostic signatures for clear cell renal cell carcinoma. ccRCCs, PPI
12  2020 A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma. ART, CI, EHCC, GBC, OR
13  2020 A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy. FFRT, MVAs, PFS, RN, SRT
14  2020 A Multi-Institutional Analysis of the Effect of Positive Surgical Margins Following Robot-Assisted Partial Nephrectomy on Oncologic Outcomes. NSM, PSM, RAPN, RFS
15  2020 A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. HDTp, HR, PFS, SCT
16  2020 A new tool for comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a pilot study from China. AML, CGA, CI, IADL
17  2020 A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. ALBI, CI, HCC, PFS, TACE-MWA
18  2020 A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. BCLC, HCC, ICG, PFS, TACE
19  2020 A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. ORR, PFI, PFS, ROC
20  2020 A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer. ADT, CAFs, HNMPCa
21  2020 A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. AGC, CERs, ICERs, PFS, SD
22  2020 A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort. GSS, GVHD, IST, NRM
23  2020 A seven long-noncoding RNA signature predicts prognosis of lung squamous cell carcinoma. lncRNAs, LSCC
24  2020 A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. AA, mCRPC, PFS
25  2020 A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. EOC, PFI, PFS, SNPs, UGs
26  2020 A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease. 3D-CRT, CI, IDO, RT, SBRT
27  2020 Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. CI, EGFR, NSCLC, PFS, PR, SD, TKI
28  2020 Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. ALC
29  2020 Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. BMI, IFI, PFS, SFI, VFI
30  2020 Adjuvant Radiation Therapy for Thoracic Soft Tissue Sarcomas: A Population-Based Analysis. CI, OR, RT, STSs
31  2020 Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer. CI, CRC, HRs, RFS
32  2020 Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. HCC, RS
33  2020 AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer. DSS, PFS, PS, TNBC
34  2020 Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis. AFR, CIs, DFS, FPR, HRs, PFS
35  2020 Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. AGR, DC, NSCLC, PD, PD, PD-L1, PFS
36  2020 Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. allo-HCT, AML, GRFS, LFS, MAC, NRM, RIC
37  2020 Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. ALK, NSCLC
38  2020 An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. CC, ORR, PDAC, QTA
39  2020 An EMT-related gene signature for the prognosis of human bladder cancer. BLCA, DFS, EMT, GSVA, MIBC, NMIBC
40  2020 An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. PFS
41  2020 Analysis of competing endogenous RNA network identifies a poorly differentiated cancer-specific RNA signature for hepatocellular carcinoma. ceRNA, lncRNAs, mRNAs, PDHCC
42  2020 Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma. LUAD, PMA, SEER
43  2020 Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. AE, anti-EGFR, DCR, EBV, ORR, PFS, RM-NPC
44  2020 Anti-PD1 antibodies in patients aged≥75 years with metastatic melanoma: A retrospective multicentre study. LDH, PFS
45  2020 Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? AMT, BBB, BM, CNS, mAb, RMT, sMDs, TPs
46  2020 Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? APC, ECOG, ESAS, HRs, PHS, PSS, TSDS
47  2020 Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. ASL-PWI, CBF, CE, GBM, IDH, MGMT, NE, PFS
48  2020 Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. AEs, CT, HRs, NDFP, RWE
49  2020 Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). CSCs, HNSCC
50  2020 Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. DDFS
51  2020 Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis. GCIG, PFS
52  2020 Assessment of the efficacy of passive cellular immunotherapy for glioma patients. KPS
53  2020 Association between radiotherapy-induced alteration of programmed death ligand1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. PD-1, PD-L1, PD-L1 IC, PD-L1 TC
54  2020 Association between socioeconomic factors at diagnosis and survival in breast cancer: A population-based study. BCSS, C-indexes
55  2020 Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. aNSCLC, irAE, MVA, PD-1 Ab
56  2020 Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma. irAEs, TTF
57  2020 Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors. NCDB
58  2020 Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. ASCT, PFS, PR
59  2020 Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade. DCR, dNLR, GI, ICBs
60  2020 Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials - an empirical analysis of bias. NSCLC, ORRs, PFS, RCTs
61  2020 Benefits of repeated resections for liver and lung metastases from colorectal cancer. RFS1, RFS2, RFS3
62  2020 Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. AVANT, CC, CI, DFS
63  2020 Bioinformatics analysis of LINC00426 expression in lung cancer and its correlation with patients' prognosis. DFS, lncRNA, NSCLC
64  2020 Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. SBRT
65  2020 Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. MM, PFS, VGPR
66  2020 Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study. GTR, PFS
67  2020 Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre-invasive phenomena that is prognostic in invasion. DFS, TAT, TF
68  2020 Bursectomy Versus Nonbursectomy for Gastric Adenocarcinoma: A Single-Center, Propensity-Score Matched Cohort Study in China. ---
69  2020 C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. CI, CRP, HR, ICIs, mRCC, NLR, PFS
70  2020 Cancer immunotherapy: Pros, cons and beyond. PFS
71  2020 Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. aRR, AYA, CUP, SEER, SES
72  2020 CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage. CSCs, GBM, PTV, RT
73  2020 CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. HPV, OPSCC, RFS, TIME
74  2020 CDK9 inhibitors reactivate p53 by downregulating iASPP. CDK9
75  2020 Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. CI, DRS, ICI, LDA, NSCLC, TIL
76  2020 Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. CI, ICIs, NLR
77  2020 Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. ER
78  2020 Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. CCI, IDS, NACT
79  2020 Characterization of Immune Dysfunction and Identification of Prognostic Immune-related Risk Factors in Acute Myeloid Leukemia. AML, EFS
80  2020 Circular RNA SMARCA5 may serve as a tumor suppressor in non-small cell lung cancer. circ-SMARCA5, DFS, NSCLC
81  2020 Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. CSCs, EPCs, HCC, HSCs
82  2020 Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. HOXA9, meth-ctDNA, OC, PFS
83  2020 Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. mCRPC, miRs
84  2020 Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. CI, ctDNA, HR, mPDAC, VAF
85  2020 Circ_0005075 stimulates the proliferation and metastasis of glioma via downregulating SIRT1. PFS, qRT-PCR
86  2020 Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). CF, CI, CTCAE, EGFR, ESCC, HR, mOS
87  2020 Claudin-1, A Double-Edged Sword in Cancer. CLDN
88  2020 Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer. EOC, FSS, RFS
89  2020 Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era. ASCT, CR, FL, HT, PFS, PR
90  2020 Clinical characteristics and prognostic factors of malignant tumors involving pterygopalatine fossa. DFS, LC, PNI, PPF
91  2020 Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea. OCCC, RFS
92  2020 Clinical course and survival in patients with squamous cell carcinoma of the maxillary alveolus and hard palate: Results from a single-center prospective cohort. DFS, END, OCSS
93  2020 Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse. EMR, MM
94  2020 Clinical features and prognostic factors in patients with esophageal cancer with bone metastasis. BMs, CEA, EC, SREs
95  2020 Clinical Features of Canine Nodal T-Cell Lymphomas Classified as CD8+ or CD4-CD8- by Flow Cytometry. PTCL, TCL, TZL
96  2020 Clinical impact of post-induction resolution of pulmonary lesions in metastatic Ewing sarcoma. CR, EFS, WLI
97  2020 Clinical impact of the CONUT score in patients with multiple myeloma. auto-PBSCT, CONUT, MM
98  2020 Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-institutional Retrospective Study. CRP, DFS, PDAC, ROC curve
99  2020 Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. CI, HR, ICIs, MV, PD, SST, UC
100  2020 Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan. ADT, CAB, CRPC, mHNPC